KRAS status and efficacy of first-line treatment of patients with metastatic colorectal cancer (mCRC) with FOLFOX with or without cetuximab: The OPUS experience
作者： C. Bokemeyer , I. Bondarenko , J. T. Hartmann , F. G. De Braud , C. Volovat
DOI: 10.1200/JCO.2008.26.15_SUPPL.4000
关键词: Real-time polymerase chain reaction 、 Performance status 、 Response rate (survey) 、 Cetuximab 、 FOLFOX 、 Medicine 、 Cancer 、 Colorectal cancer 、 Oncology 、 Internal medicine 、 KRAS
摘要: … ) or overall response, although a significantly higher response rate was achieved in patients with good performance status (ECOG 0/1) and a significantly higher curative surgery rate for …
sci-hub.st 参考文章(0)